Glycorex Transplantation AB (publ) is pleased to announce that the company has signed a distribution agreement with Rontis Hellas SA for the company's product range, Glycosorb® ABO, in Greece, covering both products within transplantation and transfusion.

Rontis is a healthcare company active in the R&D, production and international promotion of medical devices and pharmaceutical products. The organization's Greek subsidiary, Rontis Hellas SA, aside its in-house pharmaceutical & medical device R&D and production activities, it is also active in the marketing, distribution and promotion of esteemed third parties' medical devices and more particularly haemapheresis and blood bank products in Greece.

This positions them well to initiate sales of Glycosorb® ABO 4 mL in the transfusion field. As a first step, Glycosorb® ABO 4mL will be evaluated at a leading blood bank. The product facilitates the production of low-titer blood plasma and platelets, which can be administered to patients regardless of their blood group.

The Greek transfusion market is the seventh largest in the EU, and a significant share of blood components are processed using equipment from Terumo Blood and Cell Technologies, for which Rontis Hellas SA is the exclusive distributor.

In the transplantation area, just over 100 kidney transplants from living donors (LD) were performed in Greece in 2023, which is on par with Sweden. A notable difference compared to Sweden and many other European countries is that more than 40% of kidney transplants in Greece involve organs from living donors, and the number of LD has increased in recent years.

For more information, please contact:
Johan Nilsson, CEO
Email: johan.nilsson@glycorex.com, Tel: +46 46 286 5230

Brief information about the company
Glycorex Transplantation AB (publ) is a global medical technology company headquartered in Sweden. The company has developed a unique medical technology (antigen-specific immunoadsorption) to specifically reduce blood group and autoantibodies in the blood.

The company's focus areas are within transplantation, blood transfusion, and autoimmune diseases. The company has sales in over 30 countries, with Europe as its largest market. Sales take place through own sales channels and in cooperation with distributors in selected markets. 
Product development and production takes place in the company's own facility in Lund, Sweden.

Glycosorb® ABO is one of the company's self-developed proprietary medical devices that is used to facilitate blood group-incompatible transplantation by specifically reducing anti-A/B antibodies in the organ recipient's plasma. Whilst primarily used to facilitate blood group incompatible kidney transplants, Glycosorb® ABO is also used in blood group incompatible liver-, heart-, lung-, and stem cell transplants. More than 60 scientific publications have been published in reputable medical journals, showing excellent short- and long-term outcomes of blood group incompatible transplants performed with Glycosorb® ABO. Glycosorb® ABO has been used in more than 7,000 transplants in over 30 countries. 

The company has also developed and CE-marked a medical device variant of Glycosorb® ABO that targets a different customer segment: transfusion clinics and blood centers. The product can help increase the availability of universal blood components and has been shown to be effective for the preparation of low-titer blood plasma, whole blood, and platelet concentrate.
The company is collaborating with a leading European research institute to develop a product for the treatment of the autoimmune disease rheumatoid arthritis.

Glycorex Transplantation AB (publ) is listed on NGM Main Regulated Equity (Nordic Growth Market) and is traded under the symbol GTAB B.